From: Network meta-analyses performed by contracting companies and commissioned by industry
 | Company | Start date of first NMA | NMAs completed | NMAs published | NMA conducted/year | NMA published/year | Ratio published/conducted |
---|---|---|---|---|---|---|---|
1 | Mapi Group (incl. Health Technology Analysts and Optum) | Nov-05 | 88 | 33 | 9.5 | 3.6 | 0.38 |
2 | Abacus International/Decision Research Group | Jun-07 | 54 | 10 | 7.0 | 1.3 | 0.19 |
3 | Redwood Outcomes (now part of Precision Health Economics) | Sept-13 | 51 | 5 | 36 | 3.5 | 0.10 |
4 | Evidera/UBCc | Nov-08 | 50 | 3 | 8.0 | 0.48 | 0.06 |
5 | Kleijnen Systematic Reviews Ltdc | Jan-08 | 20 | 14 | 2.8 | 2.0 | 0.70 |
6 | Amaris | Jan-12 | 15 | 1 | 4.9 | 0.32 | 0.07 |
7 | Symmetron Ltd | Nov-08 | 13 | 2 | 2.1 | 0.32 | 0.15 |
8 | RTI Health Solutions | Jun-00 | 12 | 13 | 0.82 | 0.89 | 1.08 |
9 | Medignition Inc. | Aug-08 | 6 | 6 | 0.92 | 0.92 | 1.00 |
10 | Augmentium Pharma Consulting | Jan-05 | 5 | 4 | 0.50 | 0.40 | 0.80 |
11 | AHEAD | Jun-10 | 2 | 2 | 0.43 | 0.43 | 1.00 |
12 | Xintera Consulting | Jan-09 | 2 | 2 | 0.33 | 0.33 | 1.00 |
13 | CEMKA-EVAL | May-12 | 2 | 0 | 0.73 | 0.0 | 0.0 |
14 | McMDC Ltd | Sep-09 | 2 | 1 | 0.37 | 0.18 | 0.50 |
15 | Pharmacoeconomics and Outcomes Research Iberia | Jan-10 | 2 | 1 | 0.39 | 0.20 | 0.50 |
16 | BeSyRe Bekkering Systematic Reviews | May-10 | 1 | 1 | 0.21 | 0.21 | 1.00 |
17 | David Hoaglin (consulting statistician) | Jan-09 | 1 | 1 | 0.16 | 0.16 | 1.00 |
18 | Company 1c | NP | NP | NP | NP | NP | 0.04 |
19 | Company 2c | NP | NP | NPa | NP | NP | 0.08 |
 | Total | – | 476b | 106b | 6.6 | 1.5 | 0.22 |